{"schema_version":"secwatch.filing_event.v1","accession":"0001140361-23-000651","form_type":"8-K","ticker":"BNGO","cik":"0001411690","company_name":"Bionano Genomics, Inc.","filed_at":"2023-01-05T23:59:59+00:00","discovered_at":"2026-05-14T18:03:44.828551+00:00","generated_at":"2026-06-20T19:29:56.025738+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Bionano Genomics reports preliminary Q4 revenue $8.1-8.4M, up 27-33% YoY","bullets":["Full-year 2022 revenue expected $27.7-28.0M, up 54-56% vs 2021; exceeded initial guidance ranges.","Installed base of Saphyr systems reached 240 at year-end, a 46% increase over 2021.","Completed acquisition of Purigen Biosystems to accelerate OGM adoption via improved DNA prep.","Planned commercial launch of next-gen OGM system in H1 2023; NxClinical v7.0 release also expected H1 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001140361-23-000651","json":"https://secwatch.observer/filing/0001140361-23-000651.json","markdown":"https://secwatch.observer/filing/0001140361-23-000651.md","text":"https://secwatch.observer/filing/0001140361-23-000651.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1411690/000114036123000651/0001140361-23-000651-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1411690/000114036123000651/brhc10046334_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-20T19:29:56.025738+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"1cfe5b36d6afa4afd30047c458ec0ec025d438f7","claim":"Bionano Genomics, Inc. reported the year ended December 31, 2022 results: revenue $27.7 million and $28.0 million.","evidence_excerpt":"Full year 2022 revenue is expected to be in the range of $27.7 million and $28.0 million, an estimated increase of between 54% and 56% compared to 2021.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1411690/000114036123000651/0001140361-23-000651-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the year ended December 31, 2022"},{"label":"Revenue","value":"$27.7 million and $28.0 million"},{"label":"Result","value":"preliminary results"}],"fact_type":"earnings_release"},{"claim_id":"f1583964bafbe01bf90466aa3426bdf8defc53a3","claim":"Bionano Genomics, Inc. reported the fourth quarter of 2022 results: revenue $8.1 million to $8.4 million.","evidence_excerpt":"Revenues for the fourth quarter 2022 are expected to be in the range of $8.1 million to $8.4 million , an estimated increase of 12% to 16% compared to $7.2 million in the third quarter of 2022 and an estimated increase of 27% to 33% compared to the fourth quarter of 2021.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1411690/000114036123000651/0001140361-23-000651-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fourth quarter of 2022"},{"label":"Revenue","value":"$8.1 million to $8.4 million"},{"label":"Result","value":"preliminary results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}